Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection [PDF]
Bangladesh Journal of Pharmacology, 2017 Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes.
Hussien Ahmed +5 more
doaj +2 more sources
The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program [PDF]
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018 Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in ...
V. T. Ivashkin +13 more
doaj +2 more sources
NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy [PDF]
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015 The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver ...
M. V. Mayevskaya +2 more
doaj +1 more source
Reimagining Hepatitis C Elimination: Time for Actions, Not Targets. [PDF]
J Int AIDS SocJournal of the International AIDS Society, Volume 29, Issue 8, August 2026.
Klein MB, Kronfli N, Young J.
europepmc +2 more sources
Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK-Based Therapy. [PDF]
Health Sci RepABSTRACT Background Hepatitis C virus (HCV) infection is one of the leading causes of liver‐related diseases such as cirrhosis and hepatocellular carcinoma. Despite ongoing efforts, no effective vaccine has been developed to date due to the virus's high mutation rate and extensive genetic variability. This study aimed to determine the prevalence of HCV
Joukar F +3 more
europepmc +2 more sources
Sofosbuvir and daclatasvir [PDF]
British Journal of Clinical Pharmacology, 2016 Chronic hepatitis C infection is a major cause of chronic liver disease, cirrhosis and liver cancer as well as an important indication for liver transplantation. Sofosbuvir (Sovaldi®) 1 and daclatasvir (Daklinza®) 2 are new direct acting antivirals (DAAs) with a favourable safety and tolerability profile, which have significantly changed treatment for ...
Marleen H. M. Hessel +2 more
openaire +2 more sources
Terapi Kombinasi Sofosbuvir dan Daclatasvir Pada Pasien dengan Hepatitis C Kronik : Sebuah Tinjauan Literatur [PDF]
, 2023 Background: Chronic hepatitis C is a liver disease caused by the hepatitis c/HCV virus. The World Health Organization/WHO reports that more than 3% of the world's population is infected with HCV.
Ary Susilo, Samuel +4 more
core +3 more sources
Biomedical and Biotechnology Research Journal, 2022 Background: Hepatitis C virus (HCV) is the most important virus among the infectious agents as the cause of liver disease in Egypt. The aim of this work was to assess the efficacy and tolerability of the sofosbuvir + daclatasvir (±) ribavirin (SOF + DCV [
Hany Mohammed Ibrahim +3 more
doaj +1 more source
Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).
, 2021 Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).
Kuntjoro Harimurti (10035887) +3 more
core +1 more source
Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir. [PDF]
, 2017 Although new heptatis C virus treatments have increased efficacy and improved safety profiles, they also come with risk. We describe a 66-year-old white man with Child-Pugh A cirrhosis secondary to heptatis C virus genotype 3, who suffered from an acute ...
Majoni, William, Ashraf, Taha
core +2 more sources